PPD and SNBL Announce Japanese Joint Venture
PPD and Shin Nippon Biomedical Laboratories Ltd. announced an agreement to form a joint venture.
Pharmaceutical Product Development, LLC (PPD) and Shin Nippon Biomedical Laboratories Ltd. announced an agreement to form a joint venture, PPD-SNBL, that will provide clinical development services in Japan. Some of these services include Phase I-IV clinical trial monitoring, project management, site intelligence and activation, biostatistics, data management, medical writing, pharmacovigilance, regulatory and FSP services.
PPD-SNBL will combine SNBL’s clinical research division and PPD’s clinical development operations in Japan, and it will have offices in Tokyo, Osaka, and Kagoshima The transactions are subject to customary closing conditions and are expected to close in April 2015.
Read the full release here.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
